Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kazuya Shimoda

Showing results (1-10 of 214) with videos related to

Pageof 22
Sort By:
Rinsho Byori. the Japanese Journal of Clinical Pathology|June 4, 2009
[Myeloproliferative diseases caused by JAK2 mutation]Kenji Nagata, Kazuya Shimoda
[Rinsho Ketsueki] the Japanese Journal of Clinical Hematology|October 14, 2015
[Myeloproliferative neoplasms: pathophysiology and therapeutic strategy]Yoko Kubuki, Tomonori Hidaka, Kazuya Shimoda
[Rinsho Ketsueki] the Japanese Journal of Clinical Hematology|August 11, 2015
[Genetic and epigenetic abnormalities in myeloproliferative neoplasms]Takuro Kameda, Kotaro Shide, Kazuya Shimoda
[Rinsho Ketsueki] the Japanese Journal of Clinical Hematology|August 11, 2015
[Functional analysis of TET2 using a knockdown mouse model]Kotaro Shide, Takuro Kameda, Kazuya Shimoda
[Rinsho Ketsueki] the Japanese Journal of Clinical Hematology|July 6, 2018
[Myeloproliferative neoplasms: recent progresses in therapy]Ayako Kamiunten, Kotaro Shide, Kazuya Shimoda
The Korean Journal of Internal Medicine|April 19, 2018
Recent advances in the diagnosis and management of primary myelofibrosisKatsuto Takenaka, Kazuya Shimoda, Koichi Akashi
[Rinsho Ketsueki] the Japanese Journal of Clinical Hematology|September 7, 2018
[Myeloproliferative neoplasms: revisions in the 2016 WHO criteria]Tomonori Hidaka, Ayako Kamiunten, Kazuya Shimoda
Biological & Pharmaceutical Bulletin|November 1, 2021
Therapeutic Advantage of Tyk2 Inhibition for Treating Autoimmune and Chronic Inflammatory DiseasesRyuta Muromoto, Kazuya Shimoda, Kenji Oritani, et al.
International Journal of Hematology|July 1, 2024
Efficacy and safety outcomes in Japanese patients with low-risk polycythemia vera treated with ropeginterferon alfa-2bKazuya Shimoda, Albert Qin, Norio Komatsu, et al.
Case Reports in Gastroenterology|November 1, 2021
A Japanese Patient with Gaucher Disease Treated with the Oral Drug Eliglustat as Substrate Reducing TherapyNaoto Komada, Toshinari Fujiwara, Hideyuki Yoshizumi, et al.
Pageof 22

Showing results (1-10 of 214) with videos related to

Sort By:
Pageof 22
Rinsho Byori. the Japanese Journal of Clinical Pathology|June 4, 2009
[Myeloproliferative diseases caused by JAK2 mutation]Kenji Nagata, Kazuya Shimoda
[Rinsho Ketsueki] the Japanese Journal of Clinical Hematology|October 14, 2015
[Myeloproliferative neoplasms: pathophysiology and therapeutic strategy]Yoko Kubuki, Tomonori Hidaka, Kazuya Shimoda
[Rinsho Ketsueki] the Japanese Journal of Clinical Hematology|August 11, 2015
[Genetic and epigenetic abnormalities in myeloproliferative neoplasms]Takuro Kameda, Kotaro Shide, Kazuya Shimoda
[Rinsho Ketsueki] the Japanese Journal of Clinical Hematology|August 11, 2015
[Functional analysis of TET2 using a knockdown mouse model]Kotaro Shide, Takuro Kameda, Kazuya Shimoda
[Rinsho Ketsueki] the Japanese Journal of Clinical Hematology|July 6, 2018
[Myeloproliferative neoplasms: recent progresses in therapy]Ayako Kamiunten, Kotaro Shide, Kazuya Shimoda
The Korean Journal of Internal Medicine|April 19, 2018
Recent advances in the diagnosis and management of primary myelofibrosisKatsuto Takenaka, Kazuya Shimoda, Koichi Akashi
[Rinsho Ketsueki] the Japanese Journal of Clinical Hematology|September 7, 2018
[Myeloproliferative neoplasms: revisions in the 2016 WHO criteria]Tomonori Hidaka, Ayako Kamiunten, Kazuya Shimoda
Biological & Pharmaceutical Bulletin|November 1, 2021
Therapeutic Advantage of Tyk2 Inhibition for Treating Autoimmune and Chronic Inflammatory DiseasesRyuta Muromoto, Kazuya Shimoda, Kenji Oritani, et al.
International Journal of Hematology|July 1, 2024
Efficacy and safety outcomes in Japanese patients with low-risk polycythemia vera treated with ropeginterferon alfa-2bKazuya Shimoda, Albert Qin, Norio Komatsu, et al.
Case Reports in Gastroenterology|November 1, 2021
A Japanese Patient with Gaucher Disease Treated with the Oral Drug Eliglustat as Substrate Reducing TherapyNaoto Komada, Toshinari Fujiwara, Hideyuki Yoshizumi, et al.
Pageof 22